|
End-of-day quote
Nasdaq
|
5-day change | 1st Jan Change | ||
| - USD | -.--% |
|
-.--% | - |
| Market Cap | 3.21B 2.87B 2.66B 2.43B 4.58B 311B 4.6B 32.09B 12.55B 158B 12.06B 11.79B 508B | P/E 2026 * |
-15x | P/E 2027 * | 954x |
|---|---|---|---|---|---|
| Enterprise Value | 2.87B 2.57B 2.39B 2.17B 4.1B 278B 4.12B 28.72B 11.23B 142B 10.79B 10.56B 455B | EV / Sales 2026 * |
3.99x | EV / Sales 2027 * | 2.95x |
| Free-Float |
97.31% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Tarsus Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 48 | 2018-08-31 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 64 | 2023-04-23 |
| Chief Tech/Sci/R&D Officer | 47 | 2024-11-03 |
| Director | Title | Age | Since |
|---|---|---|---|
Bobak Azamian
CHM | Chairman | 48 | 2022-12-01 |
| Director/Board Member | 71 | 2019-11-30 | |
Bill Link
BRD | Director/Board Member | 80 | 2016-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 3.21B | |
| +0.83% | +3.19% | +37.87% | +106.25% | 1,051B | |
| +1.93% | +2.11% | +36.82% | +64.90% | 630B | |
| +1.49% | +5.19% | +19.84% | +85.41% | 489B | |
| +2.26% | +0.90% | +66.40% | +39.33% | 359B | |
| +1.45% | +3.50% | +21.87% | +42.64% | 344B | |
| +1.17% | +2.37% | +11.71% | +35.14% | 272B | |
| +0.89% | +1.08% | -7.28% | +10.52% | 246B | |
| +1.82% | +2.94% | +40.43% | +52.78% | 224B | |
| +2.77% | +4.44% | +29.49% | +101.40% | 187B | |
| Average | +1.46% | +2.53% | +28.57% | +59.82% | 422.63B | |
| Weighted average by Cap. | +1.47% | +2.44% | +31.57% | +69.97% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 721M 644M 598M 545M 1.03B 69.75B 1.03B 7.21B 2.82B 35.52B 2.71B 2.65B 114B | 927M 828M 770M 701M 1.32B 89.69B 1.33B 9.27B 3.62B 45.68B 3.48B 3.41B 147B |
| Net income | -218M -195M -181M -165M -311M -21.13B -313M -2.18B -854M -10.76B -820M -802M -34.57B | 6.9M 6.16M 5.73M 5.21M 9.83M 667M 9.88M 68.94M 26.96M 340M 25.9M 25.33M 1.09B |
| Net Debt | -336M -300M -279M -254M -479M -32.53B -482M -3.36B -1.31B -16.56B -1.26B -1.24B -53.21B | -476M -425M -395M -359M -678M -46.01B -681M -4.75B -1.86B -23.43B -1.79B -1.75B -75.27B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
